Cancer Biopsies Market

Executive Summary

Cancer Biopsies Market was valued at US $23.64 billion in 2021 and is projected to grow at 11.18% CAGR over the forecast period to reach US $44.65 billion by 2027. Cancer Biopsies Market represented US $4.52 billion opportunity over 2019-2021 and estimated to create US $21.01 billion opportunity in 2027 over 2021.

Cancer Biopsies from Consainsights analyses the Cancer Biopsies Market in the Life Sciences industry over the forecast period to 2027.

Cancer Biopsies research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Cancer Biopsies segmentation includes Product, Type, Application, End User and Geography.

Based on the Product, the Cancer Biopsies analysis covers Instrument, Kits and Consumables, Services.

In Product segment, Instrument segment has highest cagr growth of 9.88%.

Based on the Type, the Cancer Biopsies analysis covers Tissue Biopsy, Cancer Surgical Biopsy, Liquid Biopsy, Others.

In Type segment, Tissue Biopsy segment has highest cagr growth of 9.88%.

Based on the Application, the Cancer Biopsies analysis covers Breast Cancer, Colorectal Cancer, Cervical Cancers, Lung Cancers, Other Applications.

In Application segment, Breast Cancer segment has highest cagr growth of 9.88%.

Based on the End User, the Cancer Biopsies analysis covers Hospitals, Diagnostic Laboratories, Others.

In End User segment, Hospitals segment has highest cagr growth of 9.88%.

Based on the region, the Cancer Biopsies analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include QIAGEN N.V, Illumina, Inc., Becton, Dickinson and Company, Myriad Genetics, Thermo Fisher Scientific, Inc., BIOCEPT, INC., ANGLE plc, Hologic, Inc., Lucence Diagnostics Pte. Ltd., Danaher Corporation and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Kits and Consumables segment has the highest revenue of US $10.56 billion and is expected to grow at CAGR of 9.88% by 2027 Instrument segment has highest cagr growth of 9.88%.

Instrument

Instrument segment was valued at US $6.56 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $15.32 billion by 2027. Instrument segment represented US $1.55 billion opportunity over 2019-2021 and estimated to create US $7.21 billion opportunity in 2027 over 2021.

Kits and Consumables

Kits and Consumables segment was valued at US $8.55 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $19.96 billion by 2027. Kits and Consumables segment represented US $2.02 billion opportunity over 2019-2021 and estimated to create US $9.39 billion opportunity in 2027 over 2021.

Services

Services segment was valued at US $4.01 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $9.38 billion by 2027. Services segment represented US $0.95 billion opportunity over 2019-2021 and estimated to create US $4.41 billion opportunity in 2027 over 2021.

Type

Introduction

In 2021, Tissue Biopsy segment has the highest revenue of US $11.93 billion and is expected to grow at CAGR of 9.88% by 2027 Tissue Biopsy segment has highest cagr growth of 9.88%.

Tissue Biopsy

Tissue Biopsy segment was valued at US $9.65 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $22.53 billion by 2027. Tissue Biopsy segment represented US $2.28 billion opportunity over 2019-2021 and estimated to create US $10.60 billion opportunity in 2027 over 2021.

Cancer Surgical Biopsy

Cancer Surgical Biopsy segment was valued at US $4.90 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $11.45 billion by 2027. Cancer Surgical Biopsy segment represented US $1.16 billion opportunity over 2019-2021 and estimated to create US $5.39 billion opportunity in 2027 over 2021.

Liquid Biopsy

Liquid Biopsy segment was valued at US $2.54 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $5.94 billion by 2027. Liquid Biopsy segment represented US $0.60 billion opportunity over 2019-2021 and estimated to create US $2.79 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $2.03 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $4.74 billion by 2027. Others segment represented US $0.48 billion opportunity over 2019-2021 and estimated to create US $2.23 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Breast Cancer segment has the highest revenue of US $9.32 billion and is expected to grow at CAGR of 9.88% by 2027 Breast Cancer segment has highest cagr growth of 9.88%.

Breast Cancer

Breast Cancer segment was valued at US $7.54 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $17.61 billion by 2027. Breast Cancer segment represented US $1.78 billion opportunity over 2019-2021 and estimated to create US $8.29 billion opportunity in 2027 over 2021.

Colorectal Cancer

Colorectal Cancer segment was valued at US $4.94 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $11.52 billion by 2027. Colorectal Cancer segment represented US $1.17 billion opportunity over 2019-2021 and estimated to create US $5.42 billion opportunity in 2027 over 2021.

Cervical Cancers

Cervical Cancers segment was valued at US $2.38 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $5.55 billion by 2027. Cervical Cancers segment represented US $0.56 billion opportunity over 2019-2021 and estimated to create US $2.61 billion opportunity in 2027 over 2021.

Lung Cancers

Lung Cancers segment was valued at US $2.66 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $6.22 billion by 2027. Lung Cancers segment represented US $0.63 billion opportunity over 2019-2021 and estimated to create US $2.93 billion opportunity in 2027 over 2021.

Other Applications

Other Applications segment was valued at US $1.61 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $3.75 billion by 2027. Other Applications segment represented US $0.38 billion opportunity over 2019-2021 and estimated to create US $1.77 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Diagnostic Laboratories segment has the highest revenue of US $12.84 billion and is expected to grow at CAGR of 9.88% by 2027 Hospitals segment has highest cagr growth of 9.88%.

Hospitals

Hospitals segment was valued at US $7.34 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $17.14 billion by 2027. Hospitals segment represented US $1.73 billion opportunity over 2019-2021 and estimated to create US $8.07 billion opportunity in 2027 over 2021.

Diagnostic Laboratories

Diagnostic Laboratories segment was valued at US $10.39 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $24.26 billion by 2027. Diagnostic Laboratories segment represented US $2.45 billion opportunity over 2019-2021 and estimated to create US $11.42 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $1.39 billion in 2019 and is projected to grow at 9.88% CAGR over the forecast period to reach US $3.25 billion by 2027. Others segment represented US $0.33 billion opportunity over 2019-2021 and estimated to create US $1.53 billion opportunity in 2027 over 2021.